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INTRODUCTION
The innate immune system consists of cells and mol-
ecules which represent the first line of defence against 
microorganisms after invasion into the body. Although 
the innate immune system is not able to launch a spe-
cific attack against the pathogens, it has the ability to 
discriminate self from non-self. Special receptors on 
the surface or into the cells of innate immunity are 
bound for this task. Innate immunity receptors are 
well preserved molecules, at innate immune cell sur-
face, presenting few differences, at least structurally, 
among various species. They are called PRRs (Pat-
tern Recognition Receptors). There are also soluble 
PRRs in the plasma. PRRs recognise certain, highly 
conserved components of the pathogens, referred to 
as PAMPs (Pathogen Associated Molecular Patterns)1. 
These molecules are crucial to invaders’ survival and 
since they are present only in pathogens, their recog-
nition by PRRs offers a mechanism of discrimination 
between self and non-self at the level of innate immu-
nity2,3. PAMPs include LPS (Lipopolysaccharide) of 
Gram(-) bacteria, teichoic acids of Gram(+) bacteria, 
ds RNA of retroviruses, mannans of yeast cells and 
other molecules4,5. PRR activation by PAMPs leads 
to the production of proinflammatory cytokines and 
other mediators and thus they trigger an inflammatory 
response4.
Typically, cellular PRRs can be found on macro-
phages, dendritic cells, endothelial cells, epithelial 
cells of the mucosae, B cells and certain types of T 
lymphocytes1. PRR family includes mannose re-
ceptors, scavenger receptors, opsonin receptors, N-
forlmyl methionine receptors, TLRs (Toll Like Re-
ceptors), RLRs (RIG-I [Retinoid-inducible gene I] 
Like Receptors) and NLRs (NOD [Nucleotide Oligo-
merisation Domain] Like Receptors). Soluble PRRs 
include collectins (Mannose Binding Lectin), CRP, 
serum amyloid P, LBP (LPS Binding Protein) and 
other acute phase molecules6,7.
Human organism responds to various harmful con-
ditions with inflammation. Inflammation can be local, 
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affecting a certain part of the body, or systemic, af-
fecting the whole organism. In general, this reaction 
is useful butit canbecome dangerousin overwhelming 
conditions8. Systemic Inflammatory Response Syn-
drome (SIRS) is the term used to describe the sys-
temic inflammation due to various reasons -such as 
trauma, burns, pancreatitis, infections and others. Two 
or more of the following criteria are necessary to di-
agnose Systemic Inflammatory Response Syndrome:
Oral temperature >38oC or <36oC
Tachypnoea (>24 breaths/min) or Pa
CO2
<32 mmHg
Tachycardia (heart rate >90 beats/min)
Leucocytosis (>12000/μL), leucopenia (<4000/
μL) or >10% immature forms, in peripheral blood4,9,10.
When SIRS is caused by an infection then it is re-
ferred to as sepsis.
Sepsis is a condition representing a systemic re-
sponse to infection. It is obvious that sepsis consists of 
two essential elements: a microbial infection and the 
consequent systemic inflammation.11When sepsis, as 
defined above, is accompanied by one or more signs 
of organ dysfunction, away from the site of the initial 
infection, then it is called severe sepsis. Organs and 
systems which may be affected are the cardiovascu-
lar system (arterial systolic blood pressure less than 
90 mmHg), kidneys (urine output less than 0,5 mL/kg 
per hour despite sufficient intravenous liquid admin-
istration) and others (practically almost every system 
in the body). In severe sepsis hypotension responds 
to fluid resuscitation. When hypotension (defined as 
arterial systolic blood pressure less than 90 mmHg or 
40 mmHg less than patient’s normal level) in a patient 
with severe sepsis cannot be controlled with adequate 
liquid administration and persists at least for 1 hour 
then it is considered septic shock9. Sepsis is accompa-
nied by high mortality despite the advances in diagno-
sis and therapy4.
More than half a million patients are affected by 
severe sepsis every year in the USA.12 The incidence 
is approximately 3 patients in 1000 individuals in the 
USA and between 0,5-1,5 in 1000 individuals of pop-
ulation in Europe according to retrospective studies2, 
while it is estimated that this number will be double 
by 202013. Mortality varies between 25% -30%, which 
may raise up to 50%-60% for patients with septic 
shock14.
Sepsis is initiated by an overwhelming activation 
of innate immune system against the invader, resulting 
in an extreme cytokine production, usually referred to 
as cytokine storm15. Since pathogens are firstly sensed 
by the immune system through a number of special 
receptors called PRRs, the interaction between the in-
vaders and PRRs triggers the inflammatory response 
by inducing the production of proinflammatory and 
inflammatory cytokines, as already mentioned above. 
Thus, it seems that the first step towards sepsis is made 
at the level of these innate immunity receptors, PRRs.
CD14 on mononuclear phagocytes
CD14 is an important receptor that mostly recognises 
LPS of Gram(-) bacteria. CD14, a protein that is lo-
cated on the surface of myeloid cells, binds the LPS 
causing cellular activation. This activation leads to 
the production of proinflammatory cytokines (TNF-
a and IL-6) and chemokines (IL-8) and induces NO 
synthetase. The recognition and the signalling through 
the CD14 dependent pathways of monocyte activation 
demands three proteins: a) the protein that binds LPS 
(LBP), b) CD14 molecule and c) TLRs. LPS binding 
protein (LBP), a plasma protein that transfers lipids, 
acts on congregates of LPS or bacterial membranes 
and presents LPS monomers at the binding sites of 
CD14. It is significant that endothelium lacks mem-
brane bound CD14 and thisis why soluble CD14 is 
demanded to direct the recognition of LPS4. LPS rec-
ognition mediated by CD14 is not enough for intra-
cellular signalling. TLR-4, a receptor leading to the 
activation of the NF-κB pathway is needed for the 
activation of the intracellular signaling. This has been 
shown by the absence of activation of the pathway in 
mice that carry mutations in the intracellular region 
of TLR-4. 
Experiments held on rabbits showed that anti-
CD14mAbs administrations help to improve the hae-
modynamic status in septic shock, since they reduce 
significantly the concentrations of nitrite and nitrate 
in plasma. This indicates that improvement of the 
haemodynamic responses involve the blockage of NO 
production in vessels. So it seems that the systemic 
effects of CD14 blockage are beneficial, since they 
improve the haemodynamical status and reduce the 
demands for intracellular administration of fluids. On 
the contrary, at the point of inflammation this block-
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age is catastrophic, e.g.it prevents the intrapulmonary 
bacterial clearance. Anti-CD14 treated rabbits had 
significantly worse hypoxaemia, delayed intrapulmo-
nary bacterial clearance and a trend to higher levels of 
protein in BAL. The unfavourable results regarding 
the defective intrapulmonary bacterial clearance can-
not be attributed to reduced attraction of neutrophils 
in the lungs or to the decreased levels of cytokines, 
since both appear to be normal. It is possible that the 
anti-CD14mAbs affect the reactions between bacteria 
and leukocytes, given that phagocytosis of Gram(-) 
bacteria is facilitated by a CD14-dependent mecha-
nism in vitro16,17.
TLR
In general, TLRs form a family of transmembrane and 
intracellular receptors. Transmembrane TLRs con-
sist of an extracellular rich in leucine repeats region, 
which comes in contact with a specific PAMP for each 
TLR and an intracellular TIR region (Toll/IL-1 Re-
ceptor region) which is common between TLRs and 
IL-1 receptor and is responsible for the induction of 
the intracellular signal12,18. Each TLR shows a kind of 
specificity for certain pathogen molecules (PAMPs). 
TLR-1, -2, -4, -5 and -6 mostly recognise bacterial el-
ements while TLR-3, -7 and -8 are specific for viral 
products. TLR-9 is thought to play a role in the recog-
nition of bacteria and viruses as well (Table 1)12.
More specifically, TLR-4 interacts with the LPS of 
Gram(-) bacteria, while TLR-2 recognises mostly the 
peptidoglycan of Gram(+) bacteria19. Moreover, TLRs 
can be activated by endogenous ligands, which act like 
danger signals (alarmins)12,20. For instance it has been 
demonstrated that TLR-4 recognises oligosaccharides 
of hyaluronic acid, fibrinogen, polysaccharide frag-
ments of heparin sulphate, oxidised LDL, neutrophil 
elastase, various heat shock proteins, defensin-2 and 
HMGB-1 (High Mobility Group Box-1)12,21.
It was in 1985 when Christiane Nüsslein-Vohlard 
and her colleagues firstly described a receptor called 
Toll in Drosophila melanogaster. They showed that 
Toll receptor plays a role in the development of Dro-
sophila embryos. In 1996 Drosophila’s Toll receptor 
was found to play another important role: Jules Hoff-
man and colleagues demonstrated that this receptor 
was associated with protection against fungal infec-
tions22. Prior to that, Nomura and his co-workers, in 
Table 1. TLRs and their most important ligands. 
(*not expressed in humans, **no orthologues in humans)29,3.
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an attempt to identify some of the unidentified genes 
of the human genome, discovered a gene similar to 
that of Drosophila’s Toll, named KIAA0012, later 
mapped to chromosome 4p14, which in 1998 proved 
to be identical with TLR123,24,25.
The first receptor to be identified in human as Toll 
Like Receptor was TLR4, as TLR1, although already 
known as a gene since 1994, it was classified as TLR 
by Rock and colleagues after the description of TLR4. 
TLR4 was firstly described by Charles Janeway, Rus-
lan Medzhitov and Paula Preston as hTLR (human 
TLR) in 199726. It was only a year later when Beu-
tler and his colleagues showed that TLR4 recognises 
LPS27. Since then, many aspects of its function in the 
human immune system have been revealed and there 
are still even more to be discovered.
This review focuses on the role of TLR4, among 
other members of the TLR family, because of its par-
ticipation in the recognition of Gram(-) bacteria. This 
is quite important, as Gram negative bacteria repre-
sent one of the most common causes of sepsis with a 
very high mortality rate. Actually, almost 40% of pa-
tients with severe sepsis are proven to be infected by a 
Gram negative bacterium, while Gram positive infec-
tion is responsible for 31% of severe sepsis cases.9The 
role of TLR4 in sepsis has been tested by several ex-
perimental studies, all of which show that mice with 
certain mutations in TLR4 gene are highly resistant to 
LPS-induced sepsis but they also show dramatically 
high susceptibility to Gram negative infections28,29.
The role of LPS and TLR4 signalling cascade (Figure 1)
LPS is the principal constituent of Gram(-) bacteria 
outer membrane. It consists of three parts, the lipid A, 
a core of oligosaccharide and the O-antigen polysac-
charide. LPS causes the release of certain cytokines 
from the innate immunity cells, such as TNF-α, IL-6 
and IL-1β. LPS is identified as the causative factor in 
many cases of sepsis and septic shock31.
LPS plays a major role in the recognition of Gram 
(-) bacteria. Firstly, LPS is transferred to the surface 
of the innate immunity cells by a plasma protein 
named LBP, where it binds to CD14. CD14 deliv-
ers LPS on MD2/TLR-4 complex. There, LPS binds 
to MD2 which is attached to TLR-4. Once the pair 
LPS-MD2/TLR4 is formed, a TLR4 dimerization oc-
curs resulting in TLR-4 activation3,14,32. TLR-4 intra-
cellular region (TIR: Toll/IL-1 Receptor) comes in 
contact with many signal transmitting molecules such 
as MyD88, TIRAP (TIR domain-containing Adap-
tor Protein), TRIF (TIR domain-containing adaptor 
inducing IFN-β) and TRAM (TRIF-Related Adaptor 
Molecule). The signal follows two different path-
ways into the cytoplasm until it eventually reaches the 
nucleus. The first pathway is TIRAP- MyD88 depen-
dent (which is used by all TLRs except for TLR-3) 
and activates NF-κB and MAPKs (ERK-1/2, JNK, 
p38) causing the expression of several cytokines and 
other inflammatory molecules(e.g. IL-6, TNF-a IL-8, 
IL-12 and others), while the second one is  MyD88 
independent (it engages TRAM-TRIF molecules and 
is used by TLR-3,TLR-4, TLR-7 and TLR-9) and ac-
tivates IRF-3 (IFN response factor 3) causing produc-
tion of type I IFNs3,11. Recent studies show that Th2 
cytokines, such as IL-4, are also produced as a result 
of TLR4 activation by LPS. IL-4 production though, 
is not so rapid as that of Th1 cytokines. It seems to re-
quire both MyD-88-dependent and -independent path-
ways at the same time, in contrast to Th1 cytokines 
which need only one of them so as to be produced33.
Endogenous ligands of TLR4
The idea of discrimination between self and non-self 
has always been fundamental in immunology, mean-
ing that the immune system can only be activated by 
exogenous molecules while, on the other side, en-
dogenous molecules are not able to trigger such an 
activation. This view though, could not fully explain 
Figure 1. CD14-TLR4 activation and downstream 
signalling.
 CD14/TLR4 in Sepsis Pathogenesis and Therapy 23
all immune responses and immune homeostasis under 
certain conditions. It was then hypothesised that cer-
tain endogenous molecule also interact with the im-
mune system and, in fact, they are able to activate it. 
So, in 1994 Matzinger proposed the “danger model” 
in which the immune system is not triggered by “non-
self” but actually by certain “danger signals”, intro-
ducing the term DAMP34.
DAMPs (Danger Associated Molecular Patterns) 
are signals able to activate the innate immune system. 
This group of molecules include alarmins, which are 
danger signals originating from damaged cells, and 
PAMPs which are the exogenous molecules that are 
recognised by the immune system21.
Given that TLRs can be activated by endogenous 
DAMPs, it is quite possible that these molecules, 
among others, play a role in sepsis. HMGB-1 is an 
intracellular protein released in the extracellular envi-
ronment after cell death or damage but not after apop-
tosis. Furthermore, this molecule is also released by 
immunocompetent cells. It has been shown that cer-
tain effects of HMGB-1 in injury, inflammatory con-
ditions and sepsis are induced by its interaction with 
TLR-2, TLR-4 or both. Signalling through TLR-2 and 
-4 enhances the inflammatory response by inducing 
cytokine production and causes even more severe tis-
sue injury4,12,31. The potential role of HMGB-1 in sep-
sis pathogenesis is supported by studies showing that 
certain mutations in HMGB-1 gene are related with 
a reduced survival rate of septic patients.35Although 
HMGB-1 is always present in sepsis, its levels in 
plasma do not always correlate with the outcome or 
with the survival14. TLR-4 is part of a vicious cycle 
which enforces the inflammatory response through 
the recognition of certain DAMPs. MIP2 and neutro-
phil elastase are also components of the same cycle. 
In particular, during sepsis neutrophils are attracted 
to the lungs and liver by certain chemokines, where 
they excrete elastase. Neutrophil elastase causes tis-
sue damage but besides that, it binds to TLR-4 and 
participates to downstream activation, leading to in-
creased inflammation through chemokine production. 
Thus it closes the aforementioned cycle. This repre-
sents one of the possible mechanisms of tissue dam-
age and MODS (MultiOrgan Dysfunction Syndrome) 
in sepsis12. It seems that there is also an interaction 
between TLR-4 and complement system.Some of the 
cytokines produced through TLR activation upregu-
late the expression of C5aR and C3aR, while C5a 
component of complement system downregulates 
TLR-4-mediated responses15,36.
Clinical Prospects
As TLR4 represents a very important component in 
the pathogenesis of Gram(-) sepsis, it is quite reason-
able that it might be used as a measurable diagnos-
tic and/or prognostic factor during sepsis. Unfortu-
nately, studies up to date give conflicting data on this 
matter. There are some of these studies which show 
that TLR4 expression is upregulated in sepsis, while 
others claim that TLR4 expression makes no differ-
ence between healthy and septic patients12,37. As far 
as CD14 expression, most studies agree that CD14 is 
upregulated in sepsis. Some studies though, show that 
only the soluble CD14 is upregulated, while on the 
contrary, membrane CD14 is downregulated37.
TLR4/CD14 function during sepsis proves to be 
particularly interesting, as some studies show that 
while TLR4/CD14 expression is upregulated in sep-
tic patients, the decrease of these molecules marks 
an unfavourable outcome. Indeed, the levels of gene 
expression for TLR receptors in monocytes show to 
be related with the state of sepsis. The lowest expres-
sion happens during septic shock, followed by severe 
sepsis. That means, TLR protein expression can be as-
sociated to sepsis severity17. Thus, it seems that septic 
patients with lower TLR4/CD14 expression are more 
likely to die from sepsis17,37. From all the above men-
Figure 2. The blockade of TLR4 by Eritoran and TAK242.
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tioned, it is quite possible that TLR4/CD14 expres-
sion levels could play a prognostic and/or diagnostic 




Sepsis must be viewed as an imbalance between pro-
inflammatory and anti-inflammatory factors. Therapy 
cannot be the same for all patients, as sepsis is a quite 
complicated situation demanding a more personalised 
approach.13Spleens from patients who died from sep-
sis show decreased numbers of B and CD4+ T lym-
phocytes. Most of the patients with sepsis die during 
CARS (Compensatory Anti-inflammatory Response 
Syndrome), a later stage of sepsis, following SIRS 
and characterised by Th2 inflammatory response and 
immunoparalysis8. Given that, an immunomodulating 
therapy in those patients could be hardly helpful.
Measurements of plasma cytokines in septic pa-
tients could be used to estimate the immune status of 
each patient. A patient in CARS may benefit from a 
strengthening of his/her immunity state, as shown by 
some studies in which IFN-γ administration seems to 
increase survival13,38. On the other side, when a Th1 
response, which is responsible for further tissue dam-
age and organ failure, predominates, the appropriate 
therapy mightbe an immunosuppressive one. These 
differences in the immunocompetence profil of each 
patient are not only due to different stage - SIRS or 
CARS - but also due to the genetic background. Thus, 
in some septic patients a severe proinflammatory re-
sponse is predominant while in others an anti-inflam-
matory one is observed. This fact may explain differ-
ences in outcome of therapy in septic patients at the 
same disease stage who are treated the same way13.
PRR targeting therapies-Analogues 
A possible therapeutic approach is to target and block 
LPS before it activates innate immune response. This 
could be achieved by LBP analogues which do not 
have the ability to present LPS to CD14 on the cell 
surface, ultimately preventing TLR4 activation and 
the consequent cytokine production. Another prospect 
is offered by a recombinant soluble CD14 molecule 
which seems to increase survival of septic mice. Also, 
since the reaction between CD14 and LPS leads to the 
intracellular signalling and the production of proin-
flammatory cytokines, its blockage at this early stage 
of the inflammation cascade could possibly be used as 
a therapy. In a model of causing septic shock in a pri-
mate using endotoxin, anti-CD14mAbs prevented hy-
potension, reduced levels of cytokines in the plasma 
and the permeability of the lung epithelium. Although 
it has been proven that the blockage of CD14 is ben-
eficial, there is no data about its effects on the reaction 
between CD14 and bacteria. Furthermore, there are 
studies suggesting that HDL could act as a deposit for 
LPS which, as a result, cannot activate TLR 413.
There are many natural mechanisms which modify 
TLR expression in order to prevent an excessive ac-
tivation which could possibly be detrimental. Such a 
mechanism engages RP105, a molecule presenting 
many structural similarities with TLRs, first detect-
ed on rodent B lymphocytes. Unlike TLRs though, 
RP105 does not have an intracellular region. Its ex-
tracellular region binds to TLR4, thus offering a natu-
ral inhibitor of this receptor. The complex formed by 
RP105 and MD1 interacts with TLR4 causing a re-
duced capacity of the latter to act as a binding site 
for LPS. This complex, among other possible mecha-
nisms in humans, could be used to prevent one of the 
primary sepsis mechanisms, the excessive activation 
of TLR420. Soluble TLR4 molecules could also be 
helpful in septic conditions. A soluble TLR4 has been 
detected in mice, possibly acting as another natural 
protective mechanism from membrane bound TLR4 
hyperactivation and consequently from the production 
of an excessive amount of proinflammatory cytokines, 
a dominant factor in sepsis.
PRR targeting therapies-Monoclonal antibodies
Another important approach is that of using antibod-
ies against TLR4. The idea of blocking TLR4 with an 
antibody derives from the observation that TLR4 -/- 
mice are proven to be resistant to septic shock caused 
by E. Coli in terms of survival in comparison to wild-
typemice. It is worth noting that according to some 
studies, anti-TLR4 mAbs could possibly be used for 
prophylaxis and for therapy of sepsis as well. Experi-
ments show that in order to be effective as a therapy, 
mAbs must be administered from 1h upto 4h or even 
13h after LPS injection, depending on the bacterial 
load.14 Anti-TLR4 mAbs may be useful in sepsis ther-
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apy, as, in mice, they  inhibit the response of innate 
immunity cells exposed to LPS in vitro and in vivo as 
well. These antibodies seem to protect mice exposed 
to live E. Coli20. Another possibility is offered by 
mAbs against CD14 or against MD-2/TLR-4 complex 
as a whole, which though seem to be ineffective if ad-
ministered after infection14,39.
MyD88 also represents a possible therapeutic tar-
get. Actually, a heptapeptide called ST2825 has been 
designed to block MyD88 dimerisation and thus to 
prevent the activation of downstream molecules of the 
cascade towards the nucleus. TLR4 signalling path-
way could be possibly blocked at various points40.
TLR4 antagonists
The most promising therapy includes TLR4 antago-
nists such as Eritoran and TAK24220. Despite the pos-
sibly favourable effect of TLR4 antagonists though, 
some recent studies express the paradox that, at least 
in some cases of sepsis, TLR4 agonists could be more 
efficient41.
Eritoran (E5564) is a synthetic LPS antagonist 
binding to MD-2/TLR4 complex and it is an analogue 
of the lipid A of Rhodobacter capsulatus. Eritoran 
(E5564) and E5531 (another A lipid analogue with 
similar function to that of Eritoran) bind to TLR-4 thus 
preventing its activation by LPS (Figure 2). Eritoran 
lacks any agonistic activity on TLR4. Several studies 
have shown that the use of these analogues inhibits the 
production of all the cytokines for which TLR-4 acti-
vation by LPS is responsible18. In particular, Eritoran 
seems to block cytokine production after in vitro chal-
lenge with LPS or with live Gram(-) bacteria in whole 
human blood. In animal models it has been shown that 
a minimal dose of 1mg/kg of body weight is sufficient 
to completely block LPS induced activation of TLR4, 
while in humans it is estimated that a dose of merely 
100μg for a patient with 70kg of weight would have 
the same effect. Eritoran (E5564) is currently being 
tested in a phase III study31.
TAK-242 is another molecule that has been de-
signed to block TLR4-induced cytokine production. 
TAK-242 is a cyclohexene derivative which blocks 
the signal transduction via TLR-4 and thus it prevents 
lethality in experimental models of LPS septic shock 
or sepsis in rodents.17In fact, TAK-242 is not an an-
tagonist of TLR4 but an inhibitor binding to the intra-
cellular domain of TLR4 and specifically to Cys747. 
After binding to this site it blocks the transduction 
of the signal of both MyD-88 dependent and inde-
pendent pathways. TAK-242 is also proven to block 
TLR4 downstream signalling induced by endogenous 
ligands, such as HMGB1. TAK-242 has been tested in 
a phase III clinical trial, which proved no significant 
decrease in cytokine production compared with pla-
cebo therapy. 
Despite any good results so far, it must be kept in 
mind that TLR blocking, at any stage, could be a dou-
ble-edged sword, as an extreme blockade could result 
in an impaired immune defense against infections29,40.
CONCLUSION
Sepsis is a critical situation accompanied by high 
mortality ranging from 25% up to more than 50% for 
patient in septic shock.
In sepsis, at least in the beginning, an extreme in-
flammatory response is observed.
PRR activationis responsible for the inflammatory 
cytokine production during infection as well as dur-
ing sepsis throughup regulation during sepsis usually 
occurs.
CD14/TLR4 complex plays a critical role in the 
pathogenesis of sepsis caused by Gram(-) bacteria.
Downregulation of PRR expression in septic pa-
tients might probably be associated with higher mor-
tality.
PRR blockage (analogues, monoclonal antibod-
ies, antagonists etc.) might be beneficialduring sepsis 
treatment.
In some cases, blocking the PRR pathways might 
be detrimental rather than useful.
Questions yet to be answered
Do the PRRs have still unknown functions in sepsis 
pathogenesis, except for the expression of inflamma-
tory mediators? 
Can PRR expression measurements be efficient-
ly used to predict sepsis outcome or even to foretell 
when an infected patient is heading towards sepsis?
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ΠΕΡΙΛΗΨΗ: Η σήψη παραμένει μια από τις κύριες αιτίες θανάτου στις μονάδες εντατικής θεραπείας παγκόσμια. Φαίνεται 
ότι ένα από τα κυριότερα παθοφυσιολογικά γεγονότα στη σήψη είναι η έντονη ενεργοποίηση του ανοσιακού συσήματος, η 
οποία οδηγεί σε υπερέκκριση συγκεκριμένων μεσολαβητών της φλεγμονής. Οι υποδοχείς αναγνώρισης προτύπων δομών 
(Pattern Recognition Receptors-PRRs) είναι υπεύθυνοι για την αναγνώριση παθογόνων μέσω των κυττάρων της φυσικής 
ανοσιας και τη διαρκή παραγωγή κυτταροκινών και άλλων μεσολαβητών της φλεγμονής.. Αυτό σημαίνει ότι οι PRRs θα 
μπορούσαν να παίζουν σημαντικό ρόλο στη παθογένεση της σήψης. Από τους PRRs, ο TLR4 και ο CD14 είναι κυρίως 
υπεύθυνοι για την αναγνώριση των Gram(-) βακτηρίων, τα οποία ευθύνονται για τη σήψη στην πλειονότητα των ασθενών. 
Φαίνεται ότι η έκφραση των TLR4 και CD14 παρουσιάζει διακυμάνσεις στη σήψη. Αυτές οι διακυμάνσεις ίσως μπορούν 
να χρησιμοποιηθούν ως προγνωστικοί δείκτες στην παρακολούθηση των σηπτικών ασθενών, καθώς έχουν συσχετιστεί με 
θετική ή αρνητική έκβαση. Επίσης οι TLR4 και CD14 αποτελούν πιθανούς θεραπευτικούς στόχους. Πολλές προσπάθειες 
έχουν γίνει για αποκλεισμό αυτών των υποδοχέων σε πολλά επίπεδα, με χρήση  μονοκλωνικών αντισωμάτων, διαλυτών 
αναλόγων και κυρίως ανταγωνιστών, με άλλοτε ενθαρρυντικά και άλλοτε απογοητευτικά αποτελέσματα.
Λέξεις Κλειδιά: Ανοσολογία, Σήψη, Παθογένεση, Θεραπεία, TLR4/CD14.
Το σύμπλεγμα CD14/TLR4 στην παθογένεση και τη θεραπεία της σήψης.
Άγγελος Παζίδης, Απόστολος Χαμπίπης, Ιωάννης Γκουγκουρέλας, Παναγιώτα Μπούρα
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